US Viscosupplementation Market players march on the positive momentum of Q421 and Q122, putting the spring back into their steps.
For Q122, US Joint Fluid Replacement market players continued on a running growth, which did not seem too disrupted by the COVID Omicron variant. Furthermore, some players shared that despite physicians’ offices not yet running at 100% levels, company sales representatives were able to hold face-to-face visits and secure new orders.
Among the many topics covered in detail in our comprehensive Q122 US Joint Fluid Replacement Market Recap* are:
- Complete Q122 US Joint Fluid Market Overview and Highlights
- SmartTRAK's Expert Analysis and Insights
- All Competitor Results, including Financials and Market Shares
- Q122 Clinical Studies and Patents
- Other Notable Q122 Events
For the first quarter of 2022, the US Viscosupplementation Market achieved increased vs Q121, according to SmartTRAK Financial Dashboard. Positive aggregate revenue performance was credited to a very solid quarter for each of the US Viscosupplementation segments, with all but one experiencing double-digit growth. On a sequential basis, although the total revenue was ...
*The entire unedited article and these links can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below. 
SmartTRAK is a comprehensive, easy-to-use, business intelligence solution for the Life Sciences Industry that provides breaking updates on pertinent company news, potential treatments and guidance, international survey results, statistical analysis by country, studies, trial results, financial impact and more. All subscribers receive a Daily Updates email containing the latest need-to-know news curated by our expert analysts. It's the perfect way to start your day! If you would like to learn more about SmartTRAK, just click here.
